[Unifuzol®在间歇性关节障碍患者中的临床研究]
L V Savina1, A L Kovalenko2, A Yu Petrov3
1LLC 'Vita Eterna', 109235, Moscow, Russian Federation.
概括
联合醇® (酸氨酸) 改善了下肢动脉动脉样硬化患者的步行距离. 两种10天和20天的治疗疗程都在增强无痛和最大步行距离方面表现出显著的有效性.
科学领域:
- 血管外科 血管外科
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 下肢动脉消灭性动脉样硬化 (OLLA) 显著损害生活质量.
- 阶段II A OLLA需要有效的治疗干预措施来改善患者的流动性.
- 目前对OLLA的治疗选择可能存在局限性,需要新的方法.
研究的目的:
- 为了评估Unifuzol® (酸氨酸) 在OLLA患者的疗效和安全性.
- 为了比较10天和20天的Unifuzol®输液疗法的效果.
- 评估Unifuzol®对II期A OLLA患者的步行距离的影响.
主要方法:
- 进行了一项多中心,双盲,安慰剂控制,随机的临床试验.
- 40-65岁的460名患有II期AOLLA的患者被随机分为四组.
- 主要疗效终点包括通过跑步机测试测量的无疼痛和最大步行距离的绝对和相对增长.
主要成果:
- 治疗后10天的Unifuzol®疗程显示,治疗后30天最大步行距离 (25米) 显著增加.
- 一个20天的课程导致了无痛步行距离的显著改善 (立即23米,治疗后30天29米).
- 与基线相比,这两种治疗持续时间都显示出走路参数的统计学上显著改善.
结论:
- 用Unifuzol®进行输液治疗对II期A OLLA患者有效.
- 无论是10天或20天的Unifuzol®疗程都会产生积极的治疗结果.
- 联合醇 (Unifuzol®) 是一种可行的治疗选择,可以改善患有下肢动脉样硬化症的患者的运动能力.
更多相关视频
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
198
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
198
Acute Coronary Syndrome III: Diagnostic Studies
357
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
357
Peripheral Artery Disease III: Interprofessional Care
472
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
472
Drugs for Treatment of Ulcerative Colitis in IBD
582
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
582
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
569
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
569
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.3K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.3K


